State Pharmacy Rules for Compounded Ketamine: How Location Affects Access

State pharmacy rules for compounded ketamine determine which patients can legally receive at-home ketamine troches, oral solutions, or nasal sprays through telehealth. Because ketamine is FDA-approved only as an anesthetic, not for depression, anxiety, or PTSD, the versions used in telehealth programs are compounded, meaning a licensed pharmacy prepares them individually for each patient under a valid prescription. A pharmacy must hold a license in the state where the patient lives before it can ship that medication there. This single rule, more than prescriber licensing or platform policy, explains why compounded ketamine is available in most states but not all, and why coverage can shift as pharmacies apply for new state licenses or lose existing ones.

The FDA has approved ketamine only as an anesthetic, marketed under brand names including Ketalar. It has not approved ketamine for depression, anxiety, or PTSD. The sublingual troches, oral formulations, and nasal sprays used in telehealth ketamine programs are compounded preparations, medications a licensed compounding pharmacy custom-prepares for an individual patient under a prescription. Compounding pharmacies are legally permitted to prepare these formulations as long as they comply with applicable state and federal rules. Sublingual troches in particular are not sold as off-the-shelf pharmaceutical products; they exist specifically because of the compounding system.

Federal law splits compounding pharmacies into two categories. 503A pharmacies compound medication for individual patients against valid prescriptions and are regulated primarily by state pharmacy boards; they produce most of the ketamine troches, oral solutions, and nasal sprays used in telehealth programs. 503B outsourcing facilities compound in larger batches without individual prescriptions, register with the FDA, and follow Current Good Manufacturing Practice standards, a set of FDA quality-control requirements originally built for drug manufacturers. Some 503B facilities supply ketamine for clinical settings, but most telehealth platforms work with 503A pharmacies, where each prescription triggers preparation for that specific patient.

A pharmacy must be licensed in the state where the patient resides before it can legally ship medication there. If a patient lives in Massachusetts and the compounding pharmacy a telehealth platform uses is licensed in California, that pharmacy also needs a Massachusetts license to ship ketamine to that patient. This is the main reason access varies by state: it is a pharmacy licensing question, not just a prescriber licensing question. Major compounding pharmacies that partner with telehealth ketamine platforms typically hold licenses in most or all states specifically to support interstate shipping. Patients can verify a pharmacy's license through their state board of pharmacy's license lookup tool, or through the National Association of Boards of Pharmacy, which maintains licensure resources across states.

A small number of states add restrictions on compounding controlled substances beyond the federal framework. These can limit the quantity of compounded Schedule III substances a pharmacy may dispense, require extra documentation or physician attestation, or restrict formulations that have no FDA-approved counterpart. These state rules can create access barriers even when federal law and DEA prescribing rules are fully satisfied. Separately, the United States Pharmacopeia (USP), a nonprofit that sets quality standards for medications sold in the United States, publishes compounding standards including USP Chapter 795 for non-sterile preparations. Sublingual troches fall under USP 795. State boards generally adopt USP standards, but enforcement rigor varies by state, which can affect consistency in compounded ketamine quality. For a broader look at how telehealth ketamine regulation differs by state, see our state regulations guide.

Compounded preparations are not subject to the same manufacturing consistency requirements as FDA-approved drugs, so quality can vary between compounding pharmacies. Pharmacies that follow USP standards rigorously, submit to third-party testing, and maintain quality control programs tend to produce more consistent formulations. Less rigorous operations may produce ketamine with variable potency or purity. Our guide to choosing a provider covers how to evaluate a telehealth platform's pharmacy partnerships, and our red flags guide lists signs a platform may be cutting corners on quality. Compounding pharmacies commonly serving the telehealth ketamine market include Belmar Pharmacy, Empower Pharmacy, and Woodland Hills Pharmacy, among others.